Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | n/a | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | n/a | n/a |
Pr/Book | 0.7 |
Latest | F'cast | |
---|---|---|
Revenue | n/a | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-17 | 5.03 | 1.63 | 1.92p | 5.6 | n/a | n/a | n/a | 0.0% |
31-Dec-18 | 0.10 | (4.10) | (3.45)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-19 | n/a | (4.79) | (3.53)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-20 | n/a | (17.73) | (9.46)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | n/a | (57.86) | (24.28)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-22 | n/a | (22.15) | (11.10)p | n/a | n/a | n/a | 2.48p | 0.0% |
31-Dec-23 | n/a | (13.10) | (5.70)p | n/a | n/a | n/a | n/a | 0.0% |
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Price Monitoring Extension | 17-Jan-2023 | 16:35 | RNS |
Second Price Monitoring Extn | 13-Jan-2023 | 16:40 | RNS |
Price Monitoring Extension | 13-Jan-2023 | 16:35 | RNS |
AstraZeneca buys the rights to an asthma treatme... | 13-Jun-2014 | Daily Mail |
AstraZeneca in new £138million asthma drug deal | 13-Jun-2014 | Express & Star |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 13.10p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 203.60 |
52 Week Low | 12.35 |
Volume | 0 |
Shares Issued | 201.37m |
Market Cap | £26.38m |
RiskGrade | 510 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
CEO | Richard J Marsden |
Finance Director | John C Ward |
You are here: research